Sources

Sources

Filipczak, N., Pan, J., Yalamarty, S., & Torchilin, V. P. (2020). Recent advancements in liposome technology. Advanced drug delivery reviews156, 4–22.  

Crommelin, D., van Hoogevest, P., & Storm, G. (2020). The role of liposomes in clinical nanomedicine development. What now? Now what?Journal of controlled release : official journal of the Controlled Release Society318, 256–263.  

DeFelice SL. The nutraceutical revolution: its impact on food industry R&D. Trends Food Sci Technol 1995; 6: 59–61.

Santini, A., Cammarata, S. M., Capone, G., Ianaro, A., Tenore, G. C., Pani, L., & Novellino, E. (2018). Nutraceuticals: opening the debate for a regulatory framework. British journal of clinical pharmacology84(4), 659–672. 

Porter, C,J,, Trevaskis, N.L., Charman, W.N. (2007). Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nature Reviews Drug Discovery 6(3), 231-48.

Detopoulou, P., Panagiotakos, D. B., Antonopoulou, S., Pitsavos, C., & Stefanadis, C. (2008). Dietary choline and betaine intakes in relation to concentrations of inflammatory markers in healthy adults: the ATTICA study. The American journal of clinical nutrition87(2), 424-430.

Ehehalt, R., Wagenblast, J., Erben, G., Lehmann, W. D., Hinz, U., Merle, U., & Stremmel, W. (2004). Phosphatidylcholine and lysophosphatidylcholine in intestinal mucus of ulcerative colitis patients. A quantitative approach by nanoelectrospray‐tandem mass spectrometry. Scandinavian journal of gastroenterology39(8), 737-742.

Braun, A., Treede, I., Gotthardt, D., Tietje, A., Zahn, A., Ruhwald, R., Schoenfeld, U., Welsch, T., Kienle, P., Erben, G., Lehmann, W.D., Fuellekrug, J., Stremmel, W., Ehehalt, R. (2009). Alterations of phospholipid concentration and species composition of the intestinal mucus barrier in ulcerative colitis: a clue to pathogenesis. Inflammatory Bowel Diseases, 15(11), 1705-1720.

Stremmel, W., Merle, U., Zahn, A., Autschbach, F., Hinz, U., Ehehalt, R. (2005). Retarded release phosphatidylcholine benefits patients with chronic active ulcerative colitis. Gut, 54(7), 966-971.

Stremmel, W., Ehehalt, R., Autschbach, F., Karner, M. (2007). Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Annals of Internal Medicine, 147(9), 603-610.

Stremmel, W., Braun, A., Hanemann, A., Ehehalt, R., Autschbach, F., Karner, M. (2010). Delayed release phosphatidylcholine in chronic-active ulcerative colitis: a randomized, double-blinded, dose finding study. Journal of Clinical Gastroenterology, 44(5), e101-e107.

Karner, M., Kocjan, A., Stein, J., Schreiber, S., von Boyen, G., Uebel, P., Schmidt, C., Kupcinskas, L., Dina, I., Zuelch, F., Keilhauer, G., Stremmel, W. (2014). First multicenter study of modified release phosphatidylcholine “LT-02” in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory coursesAmerican Journal of Gastroenterology, 109(7), 1041-1051.

Li, Z., Agellon, L.B., Allen, T.M., Umeda, M., Jewell, L., Mason, A., Vance, D.E. (2006). The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis. Cell Metabolism, 3(5), 321-31.

Puri, P., Baillie, R.A., Wiest, M.M., Mirshahi, F., Choudhury, J., Cheung, O., Sargeant, C., Contos, M.J., Sanyal, A.J. (2007). A lipidomic analysis of nonalcoholic fatty liver disease. Hepatology, 46(4), 1081-1090.

Nicolson, G. L., & Ash, M. E. (2017). Membrane Lipid Replacement for chronic illnesses, aging and cancer using oral glycerolphospholipid formulations with fructooligosaccharides to restore phospholipid function in cellular membranes, organelles, cells and tissues. Biochimica et Biophysica Acta (BBA)-Biomembranes1859(9), 1704-1724.

Hirose, A., Terauchi, M, Osaka, Y., Akiyoshi, M., Kato, K., Miyasaka, N. (2018). Effect of soy lecithin on fatigue and menopausal symptoms in middle-aged women: a randomized, double-blind, placebo-controlled study. Nutrition Journal, 17(1), 1-8. 

Lieber, C.S., Robins, S.J., Li, J., DeCarli, L.M., Mak, K.M., Fasulo, J.M., Leo, M.A. (1994). Phosphatidylcholine protects against fibrosis and cirrhosis in the baboon. Gastroenterology, 106(1), 152-159.

Poly, C., Massaro, J.M., Seshadri, S., Wolf, P.A., Cho, E., Krall, E., Jacques, P.F., Au, R. (2011). The relation of dietary choline to cognitive performance and white-matter hyperintensity in the Framingham Offspring Cohort. The American Journal of Clinical Nutrition, 94(6), 1584-1591. 

Suzuki, S., Yamatoya, H., Sakai, M., Kataoka, A., Furushiro, M., Kudo, S. (2001). Oral administration of soybean lecithin transphosphatidylated phosphatidylserine improves memory impairment in aged rats. The Journal of Nutrition, 131(11), 2951-2956.

Lee, B., Sur, B.J., Han, J.J., Shim, I., Her, S., Lee, Y.S., Lee, H.J., Hahm, D.H. (2015). Oral administration of squid lecithin-transphosphatidylated phosphatidylserine improves memory impairment in aged rats. Progress in Neuro-psychopharmacology and Biological Psychiatry, 56, 1-10.

Zhou, M.M., Xue, Y., Sun, S.H., Wen, M., Li, Z.J., Xu, J., Wang, J.F., Yanagita, T., Wang, Y.M., Xue, C.H. (2016). Effects of different fatty acids composition of phosphatidylcholine on brain function of dementia mice induced by scopolamine. Lipids in Health and Disease, 15(1), 1-10. 

Küllenberg, D., Taylor, L.A., Schneider, M., Massing, U. (2012). Health effects of dietary phospholipids. Lipids in Health and Disease, 11(1), 1-16.

Additional liposome studies

Liposome technology

Akbarzadeh, A., Rezaei-Sadabady, R., Davaran, S., Joo, S.W., Zarghami, N., Hanifehpour, Y., Samiei, M., Kouhi, M., Nejati-Koshki, K. (2013). Liposome: classification, preparation, and applicationsNanoscale Research Letters 8(1), 102. doi: 10.1186/1556-276X-8-102.

Briuglia, M.L., Rotella, C., McFarlane, A., Lamprou, D.A. (2015). Influence of cholesterol on liposome stability and on in vitro drug release. Drug Delivery and Translational Research 5(3), 231-42. doi: 10.1007/s13346-015-0220-8.

Chen, W., Zou, M., Ma, X., Lv, R., Ding, T., Liu, D. (2019). Co-Encapsulation of EGCG and Quercetin in Liposomes for Optimum Antioxidant Activity. Journal of Food Science 84(1), 111-120. doi: 10.1111/1750-3841.14405.

Kraft, J.C., Freeling, J.P., Wang, Z., & Ho R.J.Y. (2014). Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. Journal of Pharmaceutical Sciences 103(1), 29–52.

Bioavailability of active compounds

Martinez, M.N., Amidon, G.L. (2002). A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. Journal of Clinical Pharmacology 42(6), 620-43.

Takahashi, M., Uechi, S., Takara, K., Asikin, Y., & Wada, K. (2009). Evaluation of an Oral Carrier System in Rats: Bioavailability and Antioxidant Properties of Liposome-Encapsulated Curcumin. Journal of Agricultural and Food Chemistry 57(19), 9141–9146.

Wajda, R., Zirkel, J., Schaffer, T. (2007). Increase of bioavailability of coenzyme Q(10) and vitamin E. Journal of Medicinal Food 10(4), 731-4.

DHA

Sun, G. Y., Simonyi, A., Fritsche, K. L., Chuang, D. Y., Hannink, M., Gu, Z., Greenlief, C. M., Yao, J. K., Lee, J. C., & Beversdorf, D. Q. (2018). Docosahexaenoic acid (DHA): An essential nutrient and a nutraceutical for brain health and diseases. Prostaglandins, leukotrienes, and essential fatty acids 136, 3–13. doi: 10.1016/j.plefa.2017.03.006.

Weiser, M. J., Butt, C. M., & Mohajeri, M. H. (2016). Docosahexaenoic Acid and Cognition throughout the Lifespan. Nutrients 8(2), 99. doi: 10.3390/nu8020099.

PEA

Davis, M. P., Behm, B., Mehta, Z., & Fernandez, C. (2019). The Potential Benefits of Palmitoylethanolamide in Palliation: A Qualitative Systematic Review. The American journal of hospice & palliative care 36(12), 1134–1154. doi: 10.1177/1049909119850807.

Mattace Raso, G., Russo, R., Calignano, A., & Meli, R. (2014). Palmitoylethanolamide in CNS health and disease. Pharmacological research 86, 32–41. doi: 10.1016/j.phrs.2014.05.006.

Lutein

Mares J. (2016). Lutein and Zeaxanthin Isomers in Eye Health and Disease. Annual review of nutrition 36, 571–602. doi: 10.1146/annurev-nutr-071715-051110.

Ranard, K. M., Jeon, S., Mohn, E. S., Griffiths, J. C., Johnson, E. J., & Erdman, J. W., Jr (2017). Dietary guidance for lutein: consideration for intake recommendations is scientifically supported. European journal of nutrition, 56(Suppl 3), 37–42. doi: 10.1007/s00394-017-1580-2.

Melatonin

Andersen, L. P., Werner, M. U., Rosenkilde, M. M., Harpsøe, N. G., Fuglsang, H., Rosenberg, J., & Gögenur, I. (2016). Pharmacokinetics of oral and intravenous melatonin in healthy volunteers. BMC pharmacology & toxicology 17, 8. doi: 10.1186/s40360-016-0052-2.

Meng, X., Li, Y., Li, S., Zhou, Y., Gan, R. Y., Xu, D. P., & Li, H. B. (2017). Dietary Sources and Bioactivities of Melatonin. Nutrients 9(4), 367. doi: 10.3390/nu9040367

CBD

Fraguas-Sánchez, A. I., & Torres-Suárez, A. I. (2018). Medical Use of Cannabinoids. Drugs 78(16), 1665–1703. doi: 10.1007/s40265-018-0996-1.

Lucas, C. J., Galettis, P., & Schneider, J. (2018). The pharmacokinetics and the pharmacodynamics of cannabinoids. British journal of clinical pharmacology 84(11), 2477–2482. doi: 10.1111/bcp.13710.

Pisanti, S., Malfitano, A. M., Ciaglia, E., Lamberti, A., Ranieri, R., Cuomo, G., Abate, M., Faggiana, G., Proto, M. C., Fiore, D., Laezza, C., & Bifulco, M. (2017). Cannabidiol: State of the art and new challenges for therapeutic applications. Pharmacology & therapeutics 175, 133–150. doi: 10.1016/j.pharmthera.2017.02.041.